Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells
Abstract
:1. Introduction
2. Results
2.1. Expression of CRY1, CRY2, HSD3B1, and HSD3B2 in Adrenal Tissues
2.2. Regulation of CRY1, CRY2, HSD3B1, and HSD3B2 Expression in HAC15 Cells
2.3. Effect of CRY1 and CRY2 Silencing in HAC15 Cells
3. Discussion
4. Materials and Methods
4.1. Patients Selection
4.2. DNA Sequencing for KCNJ5, ATP1A1, ATP2B3, and CACNA1D
4.3. Pathological Analysis
4.4. Immunohistochemistry Analyses
4.5. Cell Culture and Transfection
4.6. RNA Extraction, and Gene-Expression Studies
4.7. Statistical Analyses
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Monticone, S.; Burrello, J.; Tizzani, D.; Bertello, C.; Viola, A.; Buffolo, F.; Gabetti, L.; Mengozzi, G.; Williams, T.A.; Rabbia, F.; et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J. Am. Coll. Cardiol. 2017, 69, 1811–1820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Käyser, S.C.; Dekkers, T.; Groenewoud, H.J.; van der Wilt, G.J.; Carel Bakx, J.; van der Wel, M.C.; Hermus, A.R.; Lenders, J.W.; Deinum, J. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J. Clin. Endocrinol. Metab. 2016, 101, 2826–2835. [Google Scholar] [CrossRef] [PubMed]
- Calhoun, D.A.; Nishizaka, M.K.; Zaman, M.A.; Harding, S.M. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125, 112–117. [Google Scholar] [CrossRef] [PubMed]
- Choi, M.; Scholl, U.I.; Yue, P.; Björklund, P.; Zhao, B.; Nelson-Williams, C.; Ji, W.; Cho, Y.; Patel, A.; Men, C.J.; et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331, 768–772. [Google Scholar] [CrossRef] [PubMed]
- Azizan, E.A.; Poulsen, H.; Tuluc, P.; Zhou, J.; Clausen, M.V.; Lieb, A.; Maniero, C.; Garg, S.; Bochukova, E.G.; Zhao, W.; et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet. 2013, 45, 1055–1060. [Google Scholar] [CrossRef] [PubMed]
- Beuschlein, F.; Boulkroun, S.; Osswald, A.; Wieland, T.; Nielsen, H.N.; Lichtenauer, U.D.; Penton, D.; Schack, V.R.; Amar, L.; Fischer, E.; et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet. 2013, 45, 440–444. [Google Scholar] [CrossRef] [PubMed]
- Scholl, U.I.; Goh, G.; Stölting, G.; de Oliveira, R.C.; Choi, M.; Overton, J.D.; Fonseca, A.L.; Korah, R.; Starker, L.F.; Kunstman, J.W.; et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 2013, 45, 1050–1054. [Google Scholar] [CrossRef] [PubMed]
- Doi, M.; Takahashi, Y.; Komatsu, R.; Yamazaki, F.; Yamada, H.; Haraguchi, S.; Emoto, N.; Okuno, Y.; Tsujimoto, G.; Kanematsu, A.; et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat. Med. 2010, 16, 67–74. [Google Scholar] [CrossRef] [PubMed]
- Van Laake, L.W.; Lüscher, T.F.; Young, M.E. The circadian clock in cardiovascular regulation and disease: Lessons from the Nobel Prize in Physiology or Medicine 2017. Eur. Heart J. 2017. [Google Scholar] [CrossRef] [PubMed]
- Dunlap, J.C. Molecular bases for circadian clocks. Cell 1999, 22, 271–290. [Google Scholar] [CrossRef]
- Hattangady, N.G.; Olala, L.O.; Bollag, W.B.; Rainey, W.E. Acute and chronic regulation of aldosterone production. Mol. Cell. Endocrinol. 2012, 350, 151–162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simard, J.; Ricketts, M.L.; Gingras, S.; Soucy, P.; Feltus, F.A.; Melner, M.H. Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family. Endocr. Rev. 2005, 26, 525–582. [Google Scholar] [CrossRef] [PubMed]
- Doi, M.; Satoh, F.; Maekawa, T.; Nakamura, Y.; Fustin, J.M.; Tainaka, M.; Hotta, Y.; Takahashi, Y.; Morimoto, R.; Takase, K.; et al. Isoform-specific monoclonal antibodies against 3β-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. J. Clin. Endocrinol. Metab. 2014, 99, E257–E262. [Google Scholar] [CrossRef] [PubMed]
- Gomez-Sanchez, C.E.; Lewis, M.; Nanba, K.; Rainey, W.E.; Kuppusamy, M.; Gomez-Sanchez, E.P. Development of monoclonal antibodies against the human 3β-hydroxysteroid dehydrogenase/isomerase isozymes. Steroids 2017, 127, 56–61. [Google Scholar] [CrossRef] [PubMed]
- Konosu-Fukaya, S.; Nakamura, Y.; Satoh, F.; Felizola, S.J.; Maekawa, T.; Ono, Y.; Morimoto, R.; Ise, K.; Takeda, K.; Katsu, K.; et al. 3β-Hydroxysteroid dehydrogenase isoforms in human aldosterone-producing adenoma. Mol. Cell. Endocrinol. 2015, 408, 205–212. [Google Scholar] [CrossRef] [PubMed]
- Pamar, J.; Key, R.E.; Rainey, W.E. Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J. Clin. Endocrinol. Metab. 2008, 93, 4542–4546. [Google Scholar] [CrossRef] [PubMed]
- Monticone, S.; Else, T.; Mulatero, P.; Williams, T.A.; Rainey, W.E. Understanding primary aldosteronism: Impact of next generation sequencing and expression profiling. Mol. Cell. Endocrinol. 2015, 399, 311–320. [Google Scholar] [CrossRef] [PubMed]
- Aragao-Santiago, L.; Gomez-Sanchez, C.E.; Mulatero, P.; Spyroglou, A.; Reincke, M.; Williams, T.A. Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology. Endocrinology 2017, 158, 4129–4138. [Google Scholar] [CrossRef] [PubMed]
- Okamura, H.; Doi, M.; Goto, K.; Kojima, R. Clock genes and salt-sensitive hypertension: A new type of aldosterone-synthesizing enzyme controlled by the circadian clock and angiotensin II. Hypertens. Res. 2016, 39, 681–687. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, Y.; Felizola, S.; Satoh, F.; Konosu-Fukaya, S.; Hironobu, S. Dissecting the molecular pathways of primary aldosteronism. Pathol. Int. 2014, 64, 482–489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romero, D.G.; Rilli, S.; Plonczynski, M.W.; Yanes, L.L.; Zhou, M.Y.; Gomez-Sanchez, E.P.; Gomez-Sanchez, C.E. Adrenal transcription regulatory genes modulated by angiotensin II and their role in steroidogenesis. Physiol. Genom. 2007, 30, 26–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richards, J.; Cheng, K.Y.; All, S.; Skopis, G.; Jeffers, L.; Lynch, I.J.; Wingo, C.S.; Gumz, M.L. A role for the circadian clock protein Per1 in the regulation of aldosterone levels and renal Na+ retention. Am. J. Physiol. Renal Physiol. 2013, 305, F1697–F1704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ota, T.; Doi, M.; Yamazaki, F.; Yarimizu, D.; Okada, K.; Murai, I.; Hayashi, H.; Kunisue, S.; Nakagawa, Y.; Okamura, H. Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1. Mol. Cell. Biol. 2014, 34, 3880–3894. [Google Scholar] [CrossRef] [PubMed]
- Zhang, E.E.; Liu, A.C.; Hirota, T.; Miraglia, L.J.; Welch, G.; Pongsawakul, P.Y.; Liu, X.; Atwood, A.; Huss, J.W., 3rd; Janes, J.; et al. A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell 2009, 139, 199–210. [Google Scholar] [CrossRef] [PubMed]
- Funder, J.W.; Carey, R.M.; Fardella, C.; Gomez-Sanchez, C.E.; Mantero, F.; Stowasser, M.; Young, W.F., Jr.; Montori, V.M. Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008, 93, 3266–3281. [Google Scholar] [CrossRef] [PubMed]
- Monticone, S.; Satoh, F.; Giacchetti, G.; Viola, A.; Morimoto, R.; Kudo, M.; Iwakura, Y.; Ono, Y.; Turchi, F.; Paci, E.; et al. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension 2012, 59, 840–846. [Google Scholar] [CrossRef] [PubMed]
- Williams, T.A.; Lenders, J.W.M.; Mulatero, P.; Burrello, J.; Rottenkolber, M.; Adolf, C.; Satoh, F.; Amar, L.; Quinkler, M.; Deinum, J.; et al. Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017, 5, 689–699. [Google Scholar] [CrossRef]
- Williams, T.A.; Monticone, S.; Schack, V.R.; Stindl, J.; Burrello, J.; Buffolo, F.; Annaratone, L.; Castellano, I.; Beuschlein, F.; Reincke, M.; et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 2014, 63, 188–195. [Google Scholar] [CrossRef] [PubMed]
- Fernandes-Rosa, F.L.; Williams, T.A.; Riester, A.; Steichen, O.; Beuschlein, F.; Boulkroun, S.; Strom, T.M.; Monticone, S.; Amar, L.; Meatchi, T.; et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014, 64, 354–361. [Google Scholar] [CrossRef] [PubMed]
- Neville, A.M.; O’Hare, M.J. Histopathology of the human adrenal cortex. Clin. Endocrinol. Metab. 1985, 14, 791–820. [Google Scholar] [CrossRef]
- Monticone, S.; Castellano, I.; Versace, K.; Lucatello, B.; Veglio, F.; Gomez-Sanchez, C.E.; Williams, T.A.; Mulatero, P. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol. Cell. Endocrinol. 2015, 411, 146–154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gomez-Sanchez, C.E.; Qi, X.; Velarde-Miranda, C.; Plonczynski, M.W.; Parker, C.R.; Rainey, W.; Satoh, F.; Maekawa, T.; Nakamura, Y.; Sasano, H.; et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol. Cell. Endocrinol. 2014, 383, 111–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Monticone, S.; Bandulik, S.; Stindl, J.; Zilbermint, M.; Dedov, I.; Mulatero, P.; Allgaeuer, M.; Lee, C.C.; Stratakis, C.A.; Williams, T.A.; et al. A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. J. Clin. Endocrinol. Metab. 2015, 100, E114–E118. [Google Scholar] [CrossRef] [PubMed]
- Catt, K.J.; Cran, E.; Zimmet, P.Z.; Best, J.B.; Cain, M.D.; Coghlan, J.P. Angiotensin II blood-levels in human hypertension. Lancet 1971, 1, 459–464. [Google Scholar] [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tetti, M.; Castellano, I.; Veneziano, F.; Magnino, C.; Veglio, F.; Mulatero, P.; Monticone, S. Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. Int. J. Mol. Sci. 2018, 19, 1675. https://doi.org/10.3390/ijms19061675
Tetti M, Castellano I, Veneziano F, Magnino C, Veglio F, Mulatero P, Monticone S. Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. International Journal of Molecular Sciences. 2018; 19(6):1675. https://doi.org/10.3390/ijms19061675
Chicago/Turabian StyleTetti, Martina, Isabella Castellano, Francesca Veneziano, Corrado Magnino, Franco Veglio, Paolo Mulatero, and Silvia Monticone. 2018. "Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells" International Journal of Molecular Sciences 19, no. 6: 1675. https://doi.org/10.3390/ijms19061675